CHD7 is the most amplified CHD protein, represented in around 11% breast cancer patients (Figure 4) and its amplifications are more prevalent in aggressive breast cancer subtypes, correlating with high tumor grade and poor prognosis. Here, CHD7 is linked to neoplasm.